RU2607044C2 - Система очистки вирусных векторов - Google Patents
Система очистки вирусных векторов Download PDFInfo
- Publication number
- RU2607044C2 RU2607044C2 RU2014117466A RU2014117466A RU2607044C2 RU 2607044 C2 RU2607044 C2 RU 2607044C2 RU 2014117466 A RU2014117466 A RU 2014117466A RU 2014117466 A RU2014117466 A RU 2014117466A RU 2607044 C2 RU2607044 C2 RU 2607044C2
- Authority
- RU
- Russia
- Prior art keywords
- cell surface
- receptor
- surface marker
- vector
- ligand
- Prior art date
Links
- 239000013603 viral vector Substances 0.000 title claims abstract description 106
- 238000004140 cleaning Methods 0.000 title abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 104
- 239000002245 particle Substances 0.000 claims abstract description 54
- 239000006228 supernatant Substances 0.000 claims abstract description 48
- 239000003446 ligand Substances 0.000 claims abstract description 39
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 38
- 239000000126 substance Substances 0.000 claims abstract description 4
- 239000012634 fragment Substances 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 77
- 239000002458 cell surface marker Substances 0.000 claims description 69
- 239000013598 vector Substances 0.000 claims description 62
- 238000000746 purification Methods 0.000 claims description 46
- 238000004806 packaging method and process Methods 0.000 claims description 42
- 238000002955 isolation Methods 0.000 claims description 26
- 230000005291 magnetic effect Effects 0.000 claims description 23
- 102000005962 receptors Human genes 0.000 claims description 20
- 108020003175 receptors Proteins 0.000 claims description 20
- 239000003550 marker Substances 0.000 claims description 17
- 230000014509 gene expression Effects 0.000 claims description 16
- 230000001177 retroviral effect Effects 0.000 claims description 14
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 claims description 13
- 239000011324 bead Substances 0.000 claims description 10
- 238000012546 transfer Methods 0.000 claims description 10
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims description 8
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 claims description 8
- 102000049320 CD36 Human genes 0.000 claims description 7
- 108010045374 CD36 Antigens Proteins 0.000 claims description 7
- 102100032912 CD44 antigen Human genes 0.000 claims description 7
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 7
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 6
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 6
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 6
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 6
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 6
- 241000710929 Alphavirus Species 0.000 claims description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 claims description 3
- 239000000816 peptidomimetic Substances 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 claims 3
- 238000011534 incubation Methods 0.000 abstract description 8
- 238000012258 culturing Methods 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 238000012856 packing Methods 0.000 abstract description 2
- 238000000605 extraction Methods 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 description 41
- 241000700605 Viruses Species 0.000 description 26
- 238000004519 manufacturing process Methods 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 14
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 238000000926 separation method Methods 0.000 description 10
- 241000711975 Vesicular stomatitis virus Species 0.000 description 9
- 239000000356 contaminant Substances 0.000 description 9
- 241000710960 Sindbis virus Species 0.000 description 8
- 238000010361 transduction Methods 0.000 description 8
- 230000026683 transduction Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 238000001415 gene therapy Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 239000011325 microbead Substances 0.000 description 6
- 230000005298 paramagnetic effect Effects 0.000 description 6
- 102000000844 Cell Surface Receptors Human genes 0.000 description 5
- 108010001857 Cell Surface Receptors Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000006148 magnetic separator Substances 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241000712431 Influenza A virus Species 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000011031 large-scale manufacturing process Methods 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 210000004779 membrane envelope Anatomy 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 238000011045 prefiltration Methods 0.000 description 3
- 238000011172 small scale experimental method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 101100149252 Caenorhabditis elegans sem-5 gene Proteins 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 108700005075 Regulator Genes Proteins 0.000 description 2
- 241000712907 Retroviridae Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108010046722 Thrombospondin 1 Proteins 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 238000011173 large scale experimental method Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241001663880 Gammaretrovirus Species 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000867983 Homo sapiens C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710103500 Protein Rep78 Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 102100036034 Thrombospondin-1 Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241001521612 Tyrus Species 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 208000005925 vesicular stomatitis Diseases 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13051—Methods of production or purification of viral material
- C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
- C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11183937.9 | 2011-10-05 | ||
| EP11183937 | 2011-10-05 | ||
| PCT/EP2012/069713 WO2013050523A1 (en) | 2011-10-05 | 2012-10-05 | Viral vectors purification system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2014117466A RU2014117466A (ru) | 2015-11-10 |
| RU2607044C2 true RU2607044C2 (ru) | 2017-01-10 |
Family
ID=47071247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014117466A RU2607044C2 (ru) | 2011-10-05 | 2012-10-05 | Система очистки вирусных векторов |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20140248695A1 (https=) |
| EP (1) | EP2764094A1 (https=) |
| JP (1) | JP2014528729A (https=) |
| KR (1) | KR20140068259A (https=) |
| CN (1) | CN103842501B (https=) |
| AU (1) | AU2012320480A1 (https=) |
| BR (1) | BR112014008225A2 (https=) |
| CA (1) | CA2848939A1 (https=) |
| IL (1) | IL231876A0 (https=) |
| IN (1) | IN2014CN03368A (https=) |
| RU (1) | RU2607044C2 (https=) |
| WO (1) | WO2013050523A1 (https=) |
| ZA (1) | ZA201401481B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2480677T3 (en) | 2010-09-02 | 2015-06-15 | Molmed Spa | Semi-stable production of lentiviral vectors |
| GB201310664D0 (en) | 2013-06-14 | 2013-07-31 | Mars Inc | Feline taste receptors |
| BR112018070256A2 (pt) | 2016-03-31 | 2019-01-29 | Spark Therapeutics, Inc. | processo de fabricação de raav totalmente escalável à base de colunas |
| JP2025143019A (ja) * | 2024-03-18 | 2025-10-01 | アイポア株式会社 | ウイルスベクターの検査方法及び機械学習システム |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996027677A2 (en) * | 1995-03-07 | 1996-09-12 | Canji, Inc. | Method of purification of recombinant viral vectors containing a therapeutic gene |
| US5654183A (en) * | 1992-07-27 | 1997-08-05 | California Institute Of Technology | Genetically engineered mammalian neural crest stem cells |
| US5858744A (en) * | 1994-09-08 | 1999-01-12 | Boehringer Mannheim Gmbh | Retroviral vector hybrids and the use thereof for gene transfer |
| US20040101964A1 (en) * | 2000-05-10 | 2004-05-27 | Shigemitsu Takashima | Method of preparing virus vector |
| EP1739180A1 (en) * | 2005-06-27 | 2007-01-03 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | T cell line-based packaging cell line for the production of retroviruses by enriching of CD3 expressing cells |
| RU2301260C2 (ru) * | 2000-09-22 | 2007-06-20 | Вирэкссис Корпорейшн | Вирусные векторы с зависимой от условий репликацией и их применение |
| WO2011060218A1 (en) * | 2009-11-13 | 2011-05-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulated programmed death ligand-1 |
| WO2011067553A1 (en) * | 2009-11-26 | 2011-06-09 | King's College London | Cells for the production of biotin - tagged viral vectors or proteins |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1261847B (it) | 1993-09-01 | 1996-06-03 | San Romanello Centro Fond | Metodo per marcare cellule eucariote. |
| GB0224442D0 (en) * | 2002-10-21 | 2002-11-27 | Molmed Spa | A delivery system |
| GB0413702D0 (en) | 2004-06-18 | 2004-07-21 | Molmed Spa | Thymidine kinase |
| JP3968383B2 (ja) * | 2004-09-01 | 2007-08-29 | 株式会社日本メディカル総研 | 血液細胞の新規分類法ならびにそれを利用したテイラーメード治療および予防 |
| JP4921083B2 (ja) * | 2005-09-13 | 2012-04-18 | タカラバイオ株式会社 | レトロウィルス産生用無血清培地 |
| DK2480677T3 (en) | 2010-09-02 | 2015-06-15 | Molmed Spa | Semi-stable production of lentiviral vectors |
| WO2012028680A1 (en) | 2010-09-02 | 2012-03-08 | Molmed Spa | Semi-stable production of lentiviral vectors |
-
2012
- 2012-10-05 AU AU2012320480A patent/AU2012320480A1/en not_active Abandoned
- 2012-10-05 CN CN201280049032.XA patent/CN103842501B/zh not_active Expired - Fee Related
- 2012-10-05 EP EP12775654.2A patent/EP2764094A1/en not_active Withdrawn
- 2012-10-05 RU RU2014117466A patent/RU2607044C2/ru not_active IP Right Cessation
- 2012-10-05 JP JP2014533916A patent/JP2014528729A/ja not_active Ceased
- 2012-10-05 BR BR112014008225A patent/BR112014008225A2/pt not_active IP Right Cessation
- 2012-10-05 WO PCT/EP2012/069713 patent/WO2013050523A1/en not_active Ceased
- 2012-10-05 KR KR1020147011842A patent/KR20140068259A/ko not_active Ceased
- 2012-10-05 US US14/349,531 patent/US20140248695A1/en not_active Abandoned
- 2012-10-05 IN IN3368CHN2014 patent/IN2014CN03368A/en unknown
- 2012-10-05 CA CA2848939A patent/CA2848939A1/en not_active Abandoned
-
2014
- 2014-02-26 ZA ZA2014/01481A patent/ZA201401481B/en unknown
- 2014-04-02 IL IL231876A patent/IL231876A0/en unknown
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5654183A (en) * | 1992-07-27 | 1997-08-05 | California Institute Of Technology | Genetically engineered mammalian neural crest stem cells |
| US5858744A (en) * | 1994-09-08 | 1999-01-12 | Boehringer Mannheim Gmbh | Retroviral vector hybrids and the use thereof for gene transfer |
| WO1996027677A2 (en) * | 1995-03-07 | 1996-09-12 | Canji, Inc. | Method of purification of recombinant viral vectors containing a therapeutic gene |
| US20040101964A1 (en) * | 2000-05-10 | 2004-05-27 | Shigemitsu Takashima | Method of preparing virus vector |
| RU2301260C2 (ru) * | 2000-09-22 | 2007-06-20 | Вирэкссис Корпорейшн | Вирусные векторы с зависимой от условий репликацией и их применение |
| EP1739180A1 (en) * | 2005-06-27 | 2007-01-03 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | T cell line-based packaging cell line for the production of retroviruses by enriching of CD3 expressing cells |
| WO2011060218A1 (en) * | 2009-11-13 | 2011-05-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulated programmed death ligand-1 |
| WO2011067553A1 (en) * | 2009-11-26 | 2011-06-09 | King's College London | Cells for the production of biotin - tagged viral vectors or proteins |
Non-Patent Citations (1)
| Title |
|---|
| Ye K. ET AL. Tagging Retrovirus Vectors with a Metal Binding Peptide and One-Step Purification by Immobilized Metal Affinity Chromatography. JOURNAL OF VIROLOGY. 2004. V. 78, No.18. P. 9820-9827;. Fehse B. ET AL. Selective immunoaffinity-based enrichment of CD34+ cells transduced with retroviral vectors containing an intracytoplasmatically truncated version of the human low-affinity nerve growth factor receptor (deltaLNGFR) gene. Human gene therapy. 1997. V.8. No.15. P.1815-1824. * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20140248695A1 (en) | 2014-09-04 |
| CN103842501B (zh) | 2017-12-08 |
| IL231876A0 (en) | 2014-05-28 |
| AU2012320480A1 (en) | 2014-04-24 |
| WO2013050523A1 (en) | 2013-04-11 |
| JP2014528729A (ja) | 2014-10-30 |
| RU2014117466A (ru) | 2015-11-10 |
| KR20140068259A (ko) | 2014-06-05 |
| ZA201401481B (en) | 2015-04-29 |
| IN2014CN03368A (https=) | 2015-07-03 |
| EP2764094A1 (en) | 2014-08-13 |
| NZ623092A (en) | 2016-07-29 |
| BR112014008225A2 (pt) | 2017-04-11 |
| CA2848939A1 (en) | 2013-04-11 |
| CN103842501A (zh) | 2014-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Perry et al. | Lentiviral vector bioprocessing | |
| JP7262465B2 (ja) | Ｎｋ細胞形質導入のための方法 | |
| Bhattacharya et al. | Human immunodeficiency virus type 1 envelope glycoproteins that lack cytoplasmic domain cysteines: impact on association with membrane lipid rafts and incorporation onto budding virus particles | |
| US10724006B2 (en) | Buffers for stabilization of lentiviral preparations | |
| US5447859A (en) | Method for the purification or removal of retroviruses using sulfated cellulose | |
| Zimmermann et al. | Highly efficient concentration of lenti-and retroviral vector preparations by membrane adsorbers and ultrafiltration | |
| CN116063574A (zh) | 靶向her2的嵌合抗原受体 | |
| RU2607044C2 (ru) | Система очистки вирусных векторов | |
| US20220347316A1 (en) | Cd25 pre-selective combination anti-hiv vectors, targeting vectors, and methods of use | |
| Coroadinha | Cancer gene therapy: development and production of lentiviral vectors for gene therapy | |
| US12286639B2 (en) | LDLR negative packaging cell line for the production of VSV-G pseudotyped retroviral vector particles or virus particles thereof | |
| Coquin et al. | Syncytins enable novel possibilities to transduce human or mouse primary B cells and to achieve well-tolerated in vivo gene transfer | |
| NZ623092B2 (en) | Viral vectors purification system | |
| US20260022352A1 (en) | Compositions and methods for purifying lentivirus particles | |
| Pamukcu et al. | Lentiviral vector-based SARS-CoV-2 pseudovirus enables analysis of neutralizing activity in COVID-19 convalescent plasma | |
| Bakhshizadeh-Gashti | Purification strategy development for the recombinant vesicular stomatitis virus (rVSV) based HIV vaccine | |
| HK40058157A (en) | Buffers for stabilization of lentiviral preparations | |
| CN120988073A (zh) | 病毒包膜糖蛋白的突变体以及病毒颗粒 | |
| WO2024226858A1 (en) | Methods for viral vector manufacturing | |
| HK1253265B (en) | Buffers for stabilization of lentiviral preparations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20181006 |